Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Aug 5, 2015
Sangamo BioSciences Reports Second Quarter 2015 Financial Results

Aug 4, 2015
Sangamo BioSciences Announces Presentation At The 2015 Wedbush Pacgrow Healthcare Conference


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
7.69
Change:
+ 0.39
Day High:
7.82
Day Low:
7.30
Volume:
1,022,200
2:52 PM ET on Aug 27, 2015

Shareholder Tools